Role of Biologics in Chronic Rhinosinusitis With Nasal Polyposis: State of the Art Review

Otolaryngol Head Neck Surg. 2021 Jan;164(1):57-66. doi: 10.1177/0194599820939964. Epub 2020 Aug 4.


Objective: To review the current literature regarding the role of biologics in the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP).

Data sources: PubMed/MEDLINE, EMBASE, Cochrane Review,

Review methods: We conducted a comprehensive review of the literature on clinical studies investigating the efficacy of emerging biologics in CRSwNP, with a focus on randomized controlled trials.

Conclusions: There appears to be promising evidence to support the safety and efficacy of biologics in CRSwNP with and without asthma for select patients. However, additional large-scale randomized studies with longer follow-up are necessary to determine which patients would benefit the most from these novel systemic treatments.

Implications for practice: Chronic rhinosinusitis with nasal polyposis refractory to medical and surgical therapy remains a challenging clinical problem for otolaryngologists. However, emerging biologic therapies may offer a new therapeutic option for such patients with recalcitrant disease.

Keywords: biologics; chronic rhinosinusitis; nasal polyposis.

Publication types

  • Review

MeSH terms

  • Asthma / complications
  • Biological Products / therapeutic use*
  • Chronic Disease
  • Humans
  • Nasal Polyps / complications
  • Nasal Polyps / drug therapy*
  • Rhinitis / complications
  • Rhinitis / drug therapy*
  • Sinusitis / complications
  • Sinusitis / drug therapy*


  • Biological Products